Tag:
Duchenne muscular dystrophy
Latest Headlines
Latest Headlines
Halo garners support for PhII DMD study
Halo wants to launch a Phase II for HT-100, an oral drug designed to reduce fibrosis and promote healthy muscle fiber regeneration in DMD patients, in the second half of this year.
Halo takes the virtual approach to developing a DMD treatment
Halo Therapeutics may be the most virtual biotech company on the threshold of a mid-stage study.
AVI tanks after positive PhIIb fails to improve outcomes for DMD
AVI Biopharma heralded the news that its lead therapy hit the primary endpoint in a Phase IIb study, increasing levels of dystrophin in a tiny trial for Duchenne muscular dystrophy, but the boys did not experience a significant improvement in walking ability,
NEA turns to Europe in $30M round for RNA-drug developer Prosensa
The Dutch biotech Prosensa has rounded up 23 million euros--about $30 million--in a new round earmarked to back its work on RNA drug development for Duchenne muscular dystrophy and other rare
Two families facing DMD launch their own biotech
A severe illness would test any family. For the Secklers and Wicka families in the U.S., their sons' development of Duchenne muscular dystrophy has inspired a heroic attempt to develop a new
